Clinical significance of determination of surrogate markers of angiogenesis in breast cancer

Critical Reviews in Oncology/Hematology

Volumn 37, Issue 2, 2001, Pages 97-114

  Gasparini, Giampietro ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Angiogenesis; Breast cancer; Prognosis

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOSTATIN; ANTITHROMBIN III; BASIC FIBROBLAST GROWTH FACTOR; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LEUKEMIA INHIBITORY FACTOR; MACROPHAGE DERIVED PEPTIDE PR 39; OSTEOPONTIN; PLACENTAL GROWTH FACTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROLIFERIN; RECOMBINANT ERYTHROPOIETIN; SCATTER FACTOR; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; THYMIDINE PHOSPHORYLASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; BLOOD ANALYSIS; BREAST CANCER; CANCER INVASION; CANCER STAGING; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; METHODOLOGY; MICROVASCULARIZATION; ONCOGENE; PROGNOSIS; REVIEW; TECHNIQUE; TUMOR GROWTH; URINALYSIS;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035144670     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00105-0     Document Type: Review

References (184)

1. Tumors: wounds that not heal. Similarities between tumor stroma generation and wound healing
2. Integrins: versatility, modulation, and signaling in cell adhesion
3. Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate
4. Interactions of cancer cells with the microvasculature during metastasis
5. Tumor invasion and metastases-role of the extracellular matrix. Rhoads Memorial Award Lecture
6. Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis
7. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1
8. 3 during angiogenesis
9. Integrin signaling
10. The structural and mechanical complexity of cell-growth control
11. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α
12. Platelet-endothelium interactions
13. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo
14. Stimulation of rat peritoneal mast cell migration by tumor-derived peptides
15. The isolation and long-term culture of normal human endometrial epithelium and stroma
16. Isolation of putative progenitor endothelial cells for angiogenesis
17. Cellular and molecular mechanisms of endothelial cell dysfunction
18. Endothelial cell activation
19. Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis
20. What is the evidence that tumors are angiogenesis dependent?
21. Clinical applications of research on angiogenesis
22. Patterns of emerging mechanisms of the angiogenic switch during tumorigenesis
23. Angiogenesis in cancer, vascular, rheumatoid and other disease
24. 3 for angiogenesis
25. Clinical application of angiogenic growth factors and their inhibitors
26. Angiogenesis inhibitors generated by tumors
27. Antiangiogensis restricted tumor dormancy
28. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-trasformed epithelial cells and fibroblasts
29. Commentaries on tumor angiogenesis: an introduction
30. Oncogenes as inducers of tumor angiogenesis
31. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis
32. Regulation of angiogenesis by scatter factor
33. Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3
34. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts
35. 3
36. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1
37. Regulation of integrin function by the urokinase receptor
38. Cell adhesion and angiogenesis
39. Integrin signaling in vascular biology
40. p53 and angiogenesis in neoplasia
41. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
42. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression
43. Functions of the von Hippel-Lindau tumour suppressor protein
44. bcl-2 gene prevents apoptosis of basic fibroblast growth factor-deprived murine aortic endothelial cells
45. Endothelial apoptosis in braf-deficient mice
46. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation
47. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease
48. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression
49. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD
50. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells
51. Induction and suppression of endothelial cell apoptosis by sphingolipids: a possible in vitro model for cell-cell interactions between platelets and endothelial cell
52. The implications of angiogenesis for the biology and therapy of cancer metastasis
53. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor
54. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
55. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
56. The rationale and future potential of angiogenesis inhibitors in neoplasia
57. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma
58. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation
59. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer
60. Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients
61. Microvessel quantification and prognosis in invasive breast carcinoma
62. Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer
63. Angiogenesis quantitation as a prognostic factor for primary breast carcinoma 2 cms or less
64. Influence of tumoral microvessel density on the recurrence-free survival in human breast cancer: preliminary results
65. Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen
66. Is the relationship between angiogenesis and metastasis in breast cancer real?
67. Prognostic significance of microvessel density in lymph node negative breast carcinoma
68. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression
69. Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival
70. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma
71. Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up
72. Independent prognostic factors in breast cancer patients
73. Vascular enumeration as a significant prognosticator for invasive breast carcinoma
74. Tumour angiogenesis as a prognostic marker in infiltrating loubular carcinoma of the breast
75. Lymph node negative invasive breast carcinoma 1 centrimeter or less in size (T1a,bNOMO). Clinicopathologic features and outcome
76. The methodology of quantitation of microvessel density and prognostic value of neovascularization associated with long-term survival in japanese patients with breast cancer
77. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma
78. Macromolecular interstitital clearance, tumour vascularity, other prognostic factors and breast cancer survival
79. Tumor microvessel density and prognosis in node-negative breast cancer
80. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count and computer image analysis
81. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy
82. Breast cancer angiogenesis and tamoxifen resistance
83. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma. Results of a multiparametric study
84. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients
85. Comparison of different immunohistochemical methods in the assessment of angiogenesis: Lack of prognostic value in a group of 77 selected node-negative breast carcinomas
86. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma
87. Tumor angiogenesis in node-negative breast carcinomas-relationship with epidermal growth factor receptor, estrogen receptor, and survival
88. Microvessel density quantification in breast carcinomas
89. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis
90. Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjiuvant chemotherapy
91. The prognostic significance of tumor angiogenesis in Tawiwanese patients with invasive ductal breast carcinomas
92. Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma
93. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma
94. Assessment of angiogenesis in breast carcinoma: an important factor in prognosis?
95. Angiogenesis in breast cancer
96. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients
97. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer
98. Endothelial area as a prognostic indicator for invasive breast carcinoma
99. Prognostic significance of image morphometric microvessel enumeration in breast carcinoma
100. 3: A new prognostic indicator in breast cancer
101. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis
102. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin
103. 3 blocks human breast cancer growth and angiogenesis in human skin
104. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?
105. Tumor induction of VEGF promoter activity in stromal cells
106. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
107. Molecular and biological properties of the vascular endothelial growth factor family of proteins
108. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis
109. VEGF is required for growth and survival in neonatal mice
110. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
111. Tumor-derived expression of vascular endothelial growth factor is a critical factor expansion and vascular function
112. Vascular endothelial growth factor as a marker of tumor endothelium
113. Vascular permeability factor (VPF, VEGF) in tumor biology
114. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
115. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
116. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
117. Alternative spicing of vascular endothelial crowth factor (vegf)-r1 (flt-1) pre-mRNA is important for the regulation of vegf activity
118. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity
119. Soluble VEGF receptors
120. Thymidine phphorylase is angiogenic and promotes tumor growth
121. Angiogenic activity of enzymes
122. What is the role of thymidine phosphorylase in tumor angiogenesis?
123. Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics
124. High basal level gene expression of thymidine phosphorymase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil
125. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy
126. The ins and outs of fibroblast growth factors
127. The role of angiogenic growth factors in breast cancer progression
128. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo
129. FGF-1 but not FGF-4 secreted by carcinoma cells promotes in vitro and in vivo angiogenesis and rapid tumor proliferation
130. Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-I-B-cells: an export-dependent mechanism of action
131. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
132. Structural basis for FGF receptor dimerization and activation
133. The location of acidic fibroblast growth factor in the breast is dependent on the activity of proteases present in breast cancer tissue
134. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer
135. Quantitative analysis of vascular endothelial growth factor in primary breast cancer
136. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
137. Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications
138. Clinical relevance of vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) in patients with node-positive breast cancer treated either with adjuvant chemotherapy or hormonetherapy
139. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression
140. Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival
141. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factors, tumor growth factor β-1, platelet-derived endothelial growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
142. Markers of tumor angiogenesis and proteolysis independent define high- and low-risk subsets of node-negative cancer patients
143. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
144. p53 and vascular endothelial growth factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma
145. Does vascular endothelial growht factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?
146. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium
147. Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF
148. Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer
149. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast
150. Platelet-derived endothelial cell growth factor/hymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer
151. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma
152. Upregulation of basic fibroblast growth factor in breast cancinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival
153. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo
154. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell mobility and growth
155. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer
156. Hepatocyte growth factor/scatter factor, angiogenesis and tumour cell proliferation in primary breast cancer
157. Serum concentrations of hepatocyte growth factor in breast cancer patients
158. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
159. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of bladder cancer patients
160. Concentrations of vascular endothelial growth factor in sera of normal controls and cancer patients
161. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology
162. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease
163. Thrombocytes are the major source for soluble vascular endothelial growth factor in peropheral blood
164. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?
165. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor
166. Blood platelets and serum VEGF in cancer patients
167. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
168. Serum evaluation of basic FGF in breast cancer patients
169. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer
170. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b
171. Antiangiogenic drugs as a novel anticancer therapeutic strategy. Which are the more promising agents? What are the clinical developments and indications?
172. Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma
173. Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia
174. Assessment of tumor vascularization: immunohistochimical and non invasive methods
175. Quantitative assessment of blood flow, blood volume and blood oxygenation effects in functional magnetic resonance imaging
176. 3-targeted magnetic resonance imaging
177. Monitoring responses to antiangiogenic agents using noninvasive imaging tests
178. Automated quantification of color Doppler signals: a preliminary study in breast tumors
179. Regulation of angiogenesis via vascular endothelial growth factor receptors